Duchenne Muscular Dystrophy (DMD) Therapeutics Market Report

Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Study Report 2022 Historical Trends, Growth, and Forecast to 2028

  • POSTDATE：Mar 10, 2022
  • PAGES：158
  • REPORT CODE：GMM818356
  • REPORT SUMMARY
  • TABLE OF CONTENTS

  • Duchenne Muscular Dystrophy (DMD) Therapeutics market report explains the definition, types, applications, major countries, and major players of the Duchenne Muscular Dystrophy (DMD) Therapeutics market. The report mainly contains different types, applications, and regional historical data from 2017-2021 and forecast data from 2022-2028.

    The report contains qualitative and quantitative analysis of the entire industry.

    The influence of COVID-19 has been considered in the report. Coronavirus Impact is included in Chapter 2. In addition, Strategic Analytics to Boost Productivity and Profitability is included in Chapter 3.

    By Player:

    • Sarepta Therapeutics Inc

    • F Hoffmann-La Roche Ltd

    • Italfarmaco

    • Wave Life Sciences Ltd

    • PTC Therapeutics Inc

    By Type:

    • Pain Management Drugs

    • Corticosteroids

    • Prednisone

    • Deflazacort

    • Others

    By End-User:

    • Hospitals

    • Clinics

    • Home Care

    By Region:

    North America

    • United States

    • Canada

    • Mexico

    Europe

    • Germany

    • UK

    • Spain

    • France

    • Italy

    • Denmark

    • Finland

    • Norway

    • Sweden

    • Poland

    • Russia

    • Turkey

    Asia-Pacific

    • China

    • Japan

    • India

    • South Korea

    • Pakistan

    • Bangladesh

    • Indonesia

    • Thailand

    • Singapore

    • Malaysia

    • Philippines

    • Vietnam

    • Others

    South America

    • Brazil

    • Colombia

    • Chile

    • Argentina

    • Venezuela

    • Peru

    • Puerto Rico

    • Ecuador

    • Others

    GCC

    • Bahrain

    • Kuwait

    • Oman

    • Qatar

    • Saudi Arabia

    • United Arab Emirates

    Africa

    • Nigeria

    • South Africa

    • Egypt

    • Algeriat

    • Others

    Oceania

    • Australia

    • New Zealand

  • TABLE OF CONTENT

    1. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Executive Summary

    • 1.1 Introduction

    • 1.2 Market Panorama, 2022

    2 Coronavirus Impact

    • 2.1 Duchenne Muscular Dystrophy (DMD) Therapeutics Outlook to 2028- Original Forecasts

    • 2.2 Duchenne Muscular Dystrophy (DMD) Therapeutics Outlook to 2028- COVID-19 Affected Forecasts

    • 2.3 Impact on Industry

    3 Strategic Analytics to Boost Productivity and Profitability

    • 3.1 Potential Market Drivers and Opportunities

    • 3.2 New Challenges and Strategies

    • 3.3 Short Term and Long Term Duchenne Muscular Dystrophy (DMD) Therapeutics Market Trends

    4 Key Inferences

    5 Market Overview

    • 5.1 Current Market Scenario

    • 5.2 Porter's Five Forces Analysis

      • 5.2.1 Bargaining Power of Suppliers

      • 5.2.2 Bargaining Power of Consumers

      • 5.2.3 Threat of New Entrants

      • 5.2.4 Threat of Substitute Product and Services

      • 5.2.5 Competitive Rivalry within the Industry

    6 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market- Recent Developments

    • 6.1 Duchenne Muscular Dystrophy (DMD) Therapeutics Market News and Developments

    • 6.2 Duchenne Muscular Dystrophy (DMD) Therapeutics Market Deals Landscape

    7 Duchenne Muscular Dystrophy (DMD) Therapeutics Raw Materials and Cost Structure Analysis

    • 7.1 Duchenne Muscular Dystrophy (DMD) Therapeutics Key Raw Materials

    • 7.2 Duchenne Muscular Dystrophy (DMD) Therapeutics Price Trend of Key Raw Materials

    • 7.3 Duchenne Muscular Dystrophy (DMD) Therapeutics Key Suppliers of Raw Materials

    • 7.4 Duchenne Muscular Dystrophy (DMD) Therapeutics Market Concentration Rate of Raw Materials

    • 7.5 Duchenne Muscular Dystrophy (DMD) Therapeutics Cost Structure Analysis

      • 7.5.1 Duchenne Muscular Dystrophy (DMD) Therapeutics Raw Materials Analysis

      • 7.5.2 Duchenne Muscular Dystrophy (DMD) Therapeutics Labor Cost Analysis

      • 7.5.3 Duchenne Muscular Dystrophy (DMD) Therapeutics Manufacturing Expenses Analysis

    8 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Import and Export Analysis (Top 10 Countries)

    • 8.1 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Import by Region (Top 10 Countries) (2017-2028)

    • 8.2 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Export by Region (Top 10 Countries) (2017-2028)

    9 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Outlook by Types and Applications to 2022

    • 9.1 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Consumption and Growth Rate by Type (2017-2022)

      • 9.1.1 Global Pain Management Drugs Consumption and Growth Rate (2017-2022)

      • 9.1.2 Global Corticosteroids Consumption and Growth Rate (2017-2022)

      • 9.1.3 Global Prednisone Consumption and Growth Rate (2017-2022)

      • 9.1.4 Global Deflazacort Consumption and Growth Rate (2017-2022)

      • 9.1.5 Global Others Consumption and Growth Rate (2017-2022)

    • 9.2 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Consumption and Growth Rate by Application (2017-2022)

      • 9.2.1 Global Hospitals Consumption and Growth Rate (2017-2022)

      • 9.2.2 Global Clinics Consumption and Growth Rate (2017-2022)

      • 9.2.3 Global Home Care Consumption and Growth Rate (2017-2022)

    10 Region and Country-wise Duchenne Muscular Dystrophy (DMD) Therapeutics Market Analysis and Outlook till 2022

    • 10.1 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Consumption (2017-2022)

    • 10.2 North America Consumption Analysis

      • 10.2.1 United States Duchenne Muscular Dystrophy (DMD) Therapeutics Consumption (2017-2022)

      • 10.2.2 Canada Duchenne Muscular Dystrophy (DMD) Therapeutics Consumption (2017-2022)

      • 10.2.3 Mexico Duchenne Muscular Dystrophy (DMD) Therapeutics Consumption (2017-2022)

    • 10.3 Europe Consumption Analysis

      • 10.3.1 Germany Duchenne Muscular Dystrophy (DMD) Therapeutics Consumption (2017-2022)

      • 10.3.2 UK Duchenne Muscular Dystrophy (DMD) Therapeutics Consumption (2017-2022)

      • 10.3.3 Spain Duchenne Muscular Dystrophy (DMD) Therapeutics Consumption (2017-2022)

      • 10.3.4 Belgium Duchenne Muscular Dystrophy (DMD) Therapeutics Consumption (2017-2022)

      • 10.3.5 France Duchenne Muscular Dystrophy (DMD) Therapeutics Consumption (2017-2022)

      • 10.3.6 Italy Duchenne Muscular Dystrophy (DMD) Therapeutics Consumption (2017-2022)

      • 10.3.7 Denmark Duchenne Muscular Dystrophy (DMD) Therapeutics Consumption (2017-2022)

      • 10.3.8 Finland Duchenne Muscular Dystrophy (DMD) Therapeutics Consumption (2017-2022)

      • 10.3.9 Norway Duchenne Muscular Dystrophy (DMD) Therapeutics Consumption (2017-2022)

      • 10.3.10 Sweden Duchenne Muscular Dystrophy (DMD) Therapeutics Consumption (2017-2022)

      • 10.3.11 Poland Duchenne Muscular Dystrophy (DMD) Therapeutics Consumption (2017-2022)

      • 10.3.12 Russia Duchenne Muscular Dystrophy (DMD) Therapeutics Consumption (2017-2022)

      • 10.3.13 Turkey Duchenne Muscular Dystrophy (DMD) Therapeutics Consumption (2017-2022)

    • 10.4 APAC Consumption Analysis

      • 10.4.1 China Duchenne Muscular Dystrophy (DMD) Therapeutics Consumption (2017-2022)

      • 10.4.2 Japan Duchenne Muscular Dystrophy (DMD) Therapeutics Consumption (2017-2022)

      • 10.4.3 India Duchenne Muscular Dystrophy (DMD) Therapeutics Consumption (2017-2022)

      • 10.4.4 South Korea Duchenne Muscular Dystrophy (DMD) Therapeutics Consumption (2017-2022)

      • 10.4.5 Pakistan Duchenne Muscular Dystrophy (DMD) Therapeutics Consumption (2017-2022)

      • 10.4.6 Bangladesh Duchenne Muscular Dystrophy (DMD) Therapeutics Consumption (2017-2022)

      • 10.4.7 Indonesia Duchenne Muscular Dystrophy (DMD) Therapeutics Consumption (2017-2022)

      • 10.4.8 Thailand Duchenne Muscular Dystrophy (DMD) Therapeutics Consumption (2017-2022)

      • 10.4.9 Singapore Duchenne Muscular Dystrophy (DMD) Therapeutics Consumption (2017-2022)

      • 10.4.10 Malaysia Duchenne Muscular Dystrophy (DMD) Therapeutics Consumption (2017-2022)

      • 10.4.11 Philippines Duchenne Muscular Dystrophy (DMD) Therapeutics Consumption (2017-2022)

      • 10.4.12 Vietnam Duchenne Muscular Dystrophy (DMD) Therapeutics Consumption (2017-2022)

    • 10.5 South America Consumption Analysis

      • 10.5.1 Brazil Duchenne Muscular Dystrophy (DMD) Therapeutics Consumption (2017-2022)

      • 10.5.2 Colombia Duchenne Muscular Dystrophy (DMD) Therapeutics Consumption (2017-2022)

      • 10.5.3 Chile Duchenne Muscular Dystrophy (DMD) Therapeutics Consumption (2017-2022)

      • 10.5.4 Argentina Duchenne Muscular Dystrophy (DMD) Therapeutics Consumption (2017-2022)

      • 10.5.5 Venezuela Duchenne Muscular Dystrophy (DMD) Therapeutics Consumption (2017-2022)

      • 10.5.6 Peru Duchenne Muscular Dystrophy (DMD) Therapeutics Consumption (2017-2022)

      • 10.5.7 Puerto Rico Duchenne Muscular Dystrophy (DMD) Therapeutics Consumption (2017-2022)

      • 10.5.8 Ecuador Duchenne Muscular Dystrophy (DMD) Therapeutics Consumption (2017-2022)

    • 10.6 GCC Consumption Analysis

      • 10.6.1 Bahrain Duchenne Muscular Dystrophy (DMD) Therapeutics Consumption (2017-2022)

      • 10.6.2 Kuwait Duchenne Muscular Dystrophy (DMD) Therapeutics Consumption (2017-2022)

      • 10.6.3 Oman Duchenne Muscular Dystrophy (DMD) Therapeutics Consumption (2017-2022)

      • 10.6.4 Qatar Duchenne Muscular Dystrophy (DMD) Therapeutics Consumption (2017-2022)

      • 10.6.5 Saudi Arabia Duchenne Muscular Dystrophy (DMD) Therapeutics Consumption (2017-2022)

      • 10.6.6 United Arab Emirates Duchenne Muscular Dystrophy (DMD) Therapeutics Consumption (2017-2022)

    • 10.7 Africa Consumption Analysis

      • 10.7.1 Nigeria Duchenne Muscular Dystrophy (DMD) Therapeutics Consumption (2017-2022)

      • 10.7.2 South Africa Duchenne Muscular Dystrophy (DMD) Therapeutics Consumption (2017-2022)

      • 10.7.3 Egypt Duchenne Muscular Dystrophy (DMD) Therapeutics Consumption (2017-2022)

      • 10.7.4 Algeria Duchenne Muscular Dystrophy (DMD) Therapeutics Consumption (2017-2022)

    • 10.8 Oceania Consumption Analysis

      • 10.8.1 Australia Duchenne Muscular Dystrophy (DMD) Therapeutics Consumption (2017-2022)

      • 10.8.2 New Zealand Duchenne Muscular Dystrophy (DMD) Therapeutics Consumption (2017-2022)

    11 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Competitive Analysis

    • 11.1 Sarepta Therapeutics Inc

      • 11.1.1 Sarepta Therapeutics Inc Company Details

      • 11.1.2 Sarepta Therapeutics Inc Duchenne Muscular Dystrophy (DMD) Therapeutics Sales, Price, Value and Gross Profit (2017-2022)

      • 11.1.3 Sarepta Therapeutics Inc Duchenne Muscular Dystrophy (DMD) Therapeutics Main Business and Markets Served

      • 11.1.4 Sarepta Therapeutics Inc Duchenne Muscular Dystrophy (DMD) Therapeutics Product Portfolio

      • 11.1.5 Recent Research and Development Strategies

    • 11.2 F Hoffmann-La Roche Ltd

      • 11.2.1 F Hoffmann-La Roche Ltd Company Details

      • 11.2.2 F Hoffmann-La Roche Ltd Duchenne Muscular Dystrophy (DMD) Therapeutics Sales, Price, Value and Gross Profit (2017-2022)

      • 11.2.3 F Hoffmann-La Roche Ltd Duchenne Muscular Dystrophy (DMD) Therapeutics Main Business and Markets Served

      • 11.2.4 F Hoffmann-La Roche Ltd Duchenne Muscular Dystrophy (DMD) Therapeutics Product Portfolio

      • 11.2.5 Recent Research and Development Strategies

    • 11.3 Italfarmaco

      • 11.3.1 Italfarmaco Company Details

      • 11.3.2 Italfarmaco Duchenne Muscular Dystrophy (DMD) Therapeutics Sales, Price, Value and Gross Profit (2017-2022)

      • 11.3.3 Italfarmaco Duchenne Muscular Dystrophy (DMD) Therapeutics Main Business and Markets Served

      • 11.3.4 Italfarmaco Duchenne Muscular Dystrophy (DMD) Therapeutics Product Portfolio

      • 11.3.5 Recent Research and Development Strategies

    • 11.4 Wave Life Sciences Ltd

      • 11.4.1 Wave Life Sciences Ltd Company Details

      • 11.4.2 Wave Life Sciences Ltd Duchenne Muscular Dystrophy (DMD) Therapeutics Sales, Price, Value and Gross Profit (2017-2022)

      • 11.4.3 Wave Life Sciences Ltd Duchenne Muscular Dystrophy (DMD) Therapeutics Main Business and Markets Served

      • 11.4.4 Wave Life Sciences Ltd Duchenne Muscular Dystrophy (DMD) Therapeutics Product Portfolio

      • 11.4.5 Recent Research and Development Strategies

    • 11.5 PTC Therapeutics Inc

      • 11.5.1 PTC Therapeutics Inc Company Details

      • 11.5.2 PTC Therapeutics Inc Duchenne Muscular Dystrophy (DMD) Therapeutics Sales, Price, Value and Gross Profit (2017-2022)

      • 11.5.3 PTC Therapeutics Inc Duchenne Muscular Dystrophy (DMD) Therapeutics Main Business and Markets Served

      • 11.5.4 PTC Therapeutics Inc Duchenne Muscular Dystrophy (DMD) Therapeutics Product Portfolio

      • 11.5.5 Recent Research and Development Strategies

    12 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Outlook by Types and Applications to 2028

    • 12.1 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Consumption Forecast and Growth Rate by Type (2022-2028)

      • 12.1.1 Global Pain Management Drugs Consumption Forecast and Growth Rate (2022-2028)

      • 12.1.2 Global Corticosteroids Consumption Forecast and Growth Rate (2022-2028)

      • 12.1.3 Global Prednisone Consumption Forecast and Growth Rate (2022-2028)

      • 12.1.4 Global Deflazacort Consumption Forecast and Growth Rate (2022-2028)

      • 12.1.5 Global Others Consumption Forecast and Growth Rate (2022-2028)

    • 12.2 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Consumption Forecast and Growth Rate by Application (2022-2028)

      • 12.2.1 Global Hospitals Consumption Forecast and Growth Rate (2022-2028)

      • 12.2.2 Global Clinics Consumption Forecast and Growth Rate (2022-2028)

      • 12.2.3 Global Home Care Consumption Forecast and Growth Rate (2022-2028)

    13 Country-wise Duchenne Muscular Dystrophy (DMD) Therapeutics Market Analysis and Outlook to 2028

    • 13.1 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Consumption Forecast (2022-2028)

    • 13.2 North America Consumption Analysis

      • 13.2.1 United States Duchenne Muscular Dystrophy (DMD) Therapeutics Consumption Forecast (2022-2028)

      • 13.2.2 Canada Duchenne Muscular Dystrophy (DMD) Therapeutics Consumption Forecast (2022-2028)

      • 13.2.3 Mexico Duchenne Muscular Dystrophy (DMD) Therapeutics Consumption Forecast (2022-2028)

    • 13.3 Europe Consumption Analysis

      • 13.3.1 Germany Duchenne Muscular Dystrophy (DMD) Therapeutics Consumption Forecast (2022-2028)

      • 13.3.2 UK Duchenne Muscular Dystrophy (DMD) Therapeutics Consumption Forecast (2022-2028)

      • 13.3.3 Spain Duchenne Muscular Dystrophy (DMD) Therapeutics Consumption Forecast (2022-2028)

      • 13.3.4 Belgium Duchenne Muscular Dystrophy (DMD) Therapeutics Consumption Forecast (2022-2028)

      • 13.3.5 France Duchenne Muscular Dystrophy (DMD) Therapeutics Consumption Forecast (2022-2028)

      • 13.3.6 Italy Duchenne Muscular Dystrophy (DMD) Therapeutics Consumption Forecast (2022-2028)

      • 13.3.7 Denmark Duchenne Muscular Dystrophy (DMD) Therapeutics Consumption Forecast (2022-2028)

      • 13.3.8 Finland Duchenne Muscular Dystrophy (DMD) Therapeutics Consumption Forecast (2022-2028)

      • 13.3.9 Norway Duchenne Muscular Dystrophy (DMD) Therapeutics Consumption Forecast (2022-2028)

      • 13.3.10 Sweden Duchenne Muscular Dystrophy (DMD) Therapeutics Consumption Forecast (2022-2028)

      • 13.3.11 Poland Duchenne Muscular Dystrophy (DMD) Therapeutics Consumption Forecast (2022-2028)

      • 13.3.12 Russia Duchenne Muscular Dystrophy (DMD) Therapeutics Consumption Forecast (2022-2028)

      • 13.3.13 Turkey Duchenne Muscular Dystrophy (DMD) Therapeutics Consumption Forecast (2022-2028)

    • 13.4 APAC Consumption Analysis

      • 13.4.1 China Duchenne Muscular Dystrophy (DMD) Therapeutics Consumption Forecast (2022-2028)

      • 13.4.2 Japan Duchenne Muscular Dystrophy (DMD) Therapeutics Consumption Forecast (2022-2028)

      • 13.4.3 India Duchenne Muscular Dystrophy (DMD) Therapeutics Consumption Forecast (2022-2028)

      • 13.4.4 South Korea Duchenne Muscular Dystrophy (DMD) Therapeutics Consumption Forecast (2022-2028)

      • 13.4.5 Pakistan Duchenne Muscular Dystrophy (DMD) Therapeutics Consumption Forecast (2022-2028)

      • 13.4.6 Bangladesh Duchenne Muscular Dystrophy (DMD) Therapeutics Consumption Forecast (2022-2028)

      • 13.4.7 Indonesia Duchenne Muscular Dystrophy (DMD) Therapeutics Consumption Forecast (2022-2028)

      • 13.4.8 Thailand Duchenne Muscular Dystrophy (DMD) Therapeutics Consumption Forecast (2022-2028)

      • 13.4.9 Singapore Duchenne Muscular Dystrophy (DMD) Therapeutics Consumption Forecast (2022-2028)

      • 13.4.10 Malaysia Duchenne Muscular Dystrophy (DMD) Therapeutics Consumption Forecast (2022-2028)

      • 13.4.11 Philippines Duchenne Muscular Dystrophy (DMD) Therapeutics Consumption Forecast (2022-2028)

      • 13.4.12 Vietnam Duchenne Muscular Dystrophy (DMD) Therapeutics Consumption Forecast (2022-2028)

    • 13.5 South America Consumption Analysis

      • 13.5.1 Brazil Duchenne Muscular Dystrophy (DMD) Therapeutics Consumption Forecast (2022-2028)

      • 13.5.2 Colombia Duchenne Muscular Dystrophy (DMD) Therapeutics Consumption Forecast (2022-2028)

      • 13.5.3 Chile Duchenne Muscular Dystrophy (DMD) Therapeutics Consumption Forecast (2022-2028)

      • 13.5.4 Argentina Duchenne Muscular Dystrophy (DMD) Therapeutics Consumption Forecast (2022-2028)

      • 13.5.5 Venezuela Duchenne Muscular Dystrophy (DMD) Therapeutics Consumption Forecast (2022-2028)

      • 13.5.6 Peru Duchenne Muscular Dystrophy (DMD) Therapeutics Consumption Forecast (2022-2028)

      • 13.5.7 Puerto Rico Duchenne Muscular Dystrophy (DMD) Therapeutics Consumption Forecast (2022-2028)

      • 13.5.8 Ecuador Duchenne Muscular Dystrophy (DMD) Therapeutics Consumption Forecast (2022-2028)

    • 13.6 GCC Consumption Analysis

      • 13.6.1 Bahrain Duchenne Muscular Dystrophy (DMD) Therapeutics Consumption Forecast (2022-2028)

      • 13.6.2 Kuwait Duchenne Muscular Dystrophy (DMD) Therapeutics Consumption Forecast (2022-2028)

      • 13.6.3 Oman Duchenne Muscular Dystrophy (DMD) Therapeutics Consumption Forecast (2022-2028)

      • 13.6.4 Qatar Duchenne Muscular Dystrophy (DMD) Therapeutics Consumption Forecast (2022-2028)

      • 13.6.5 Saudi Arabia Duchenne Muscular Dystrophy (DMD) Therapeutics Consumption Forecast (2022-2028)

      • 13.6.6 United Arab Emirates Duchenne Muscular Dystrophy (DMD) Therapeutics Consumption Forecast (2022-2028)

    • 13.7 Africa Consumption Analysis

      • 13.7.1 Nigeria Duchenne Muscular Dystrophy (DMD) Therapeutics Consumption Forecast (2022-2028)

      • 13.7.2 South Africa Duchenne Muscular Dystrophy (DMD) Therapeutics Consumption Forecast (2022-2028)

      • 13.7.3 Egypt Duchenne Muscular Dystrophy (DMD) Therapeutics Consumption Forecast (2022-2028)

      • 13.7.4 Algeria Duchenne Muscular Dystrophy (DMD) Therapeutics Consumption Forecast (2022-2028)

    • 13.8 Oceania Consumption Analysis

      • 13.8.1 Australia Duchenne Muscular Dystrophy (DMD) Therapeutics Consumption Forecast (2022-2028)

      • 13.8.2 New Zealand Duchenne Muscular Dystrophy (DMD) Therapeutics Consumption Forecast (2022-2028)

    14 Conclusions


    The List of Tables and Figures

    • Table Definition of Duchenne Muscular Dystrophy (DMD) Therapeutics

    • Figure of Duchenne Muscular Dystrophy (DMD) Therapeutics Picture

    • Table Global Duchenne Muscular Dystrophy (DMD) Therapeutics Import by Region (Top 10 Countries) (2017-2028)

    • Table Global Duchenne Muscular Dystrophy (DMD) Therapeutics Export by Region (Top 10 Countries) (2017-2028)

    • Figure Global Pain Management Drugs Consumption and Growth Rate (2017-2022)

    • Figure Global Corticosteroids Consumption and Growth Rate (2017-2022)

    • Figure Global Prednisone Consumption and Growth Rate (2017-2022)

    • Figure Global Deflazacort Consumption and Growth Rate (2017-2022)

    • Figure Global Others Consumption and Growth Rate (2017-2022)

    • Figure Global Hospitals Consumption and Growth Rate (2017-2022)

    • Figure Global Clinics Consumption and Growth Rate (2017-2022)

    • Figure Global Home Care Consumption and Growth Rate (2017-2022)

    • Figure Global Duchenne Muscular Dystrophy (DMD) Therapeutics Consumption by Country (2017-2022)

    • Table North America Duchenne Muscular Dystrophy (DMD) Therapeutics Consumption by Country (2017-2022)

    • Figure United States Duchenne Muscular Dystrophy (DMD) Therapeutics Consumption and Growth Rate (2017-2022)

    • Figure Canada Duchenne Muscular Dystrophy (DMD) Therapeutics Consumption and Growth Rate (2017-2022)

    • Figure Mexico Duchenne Muscular Dystrophy (DMD) Therapeutics Consumption and Growth Rate (2017-2022)

    • Table Europe Duchenne Muscular Dystrophy (DMD) Therapeutics Consumption by Country (2017-2022)

    • Figure Germany Duchenne Muscular Dystrophy (DMD) Therapeutics Consumption and Growth Rate (2017-2022)

    • Figure UK Duchenne Muscular Dystrophy (DMD) Therapeutics Consumption and Growth Rate (2017-2022)

    • Figure Spain Duchenne Muscular Dystrophy (DMD) Therapeutics Consumption and Growth Rate (2017-2022)

    • Figure Belgium Duchenne Muscular Dystrophy (DMD) Therapeutics Consumption and Growth Rate (2017-2022)

    • Figure France Duchenne Muscular Dystrophy (DMD) Therapeutics Consumption and Growth Rate (2017-2022)

    • Figure Italy Duchenne Muscular Dystrophy (DMD) Therapeutics Consumption and Growth Rate (2017-2022)

    • Figure Denmark Duchenne Muscular Dystrophy (DMD) Therapeutics Consumption and Growth Rate (2017-2022)

    • Figure Finland Duchenne Muscular Dystrophy (DMD) Therapeutics Consumption and Growth Rate (2017-2022)

    • Figure Norway Duchenne Muscular Dystrophy (DMD) Therapeutics Consumption and Growth Rate (2017-2022)

    • Figure Sweden Duchenne Muscular Dystrophy (DMD) Therapeutics Consumption and Growth Rate (2017-2022)

    • Figure Poland Duchenne Muscular Dystrophy (DMD) Therapeutics Consumption and Growth Rate (2017-2022)

    • Figure Russia Duchenne Muscular Dystrophy (DMD) Therapeutics Consumption and Growth Rate (2017-2022)

    • Figure Turkey Duchenne Muscular Dystrophy (DMD) Therapeutics Consumption and Growth Rate (2017-2022)

    • Table APAC Duchenne Muscular Dystrophy (DMD) Therapeutics Consumption by Country (2017-2022)

    • Figure China Duchenne Muscular Dystrophy (DMD) Therapeutics Consumption and Growth Rate (2017-2022)

    • Figure Japan Duchenne Muscular Dystrophy (DMD) Therapeutics Consumption and Growth Rate (2017-2022)

    • Figure India Duchenne Muscular Dystrophy (DMD) Therapeutics Consumption and Growth Rate (2017-2022)

    • Figure South Korea Duchenne Muscular Dystrophy (DMD) Therapeutics Consumption and Growth Rate (2017-2022)

    • Figure Pakistan Duchenne Muscular Dystrophy (DMD) Therapeutics Consumption and Growth Rate (2017-2022)

    • Figure Bangladesh Duchenne Muscular Dystrophy (DMD) Therapeutics Consumption and Growth Rate (2017-2022)

    • Figure Indonesia Duchenne Muscular Dystrophy (DMD) Therapeutics Consumption and Growth Rate (2017-2022)

    • Figure Thailand Duchenne Muscular Dystrophy (DMD) Therapeutics Consumption and Growth Rate (2017-2022)

    • Figure Singapore Duchenne Muscular Dystrophy (DMD) Therapeutics Consumption and Growth Rate (2017-2022)

    • Figure Malaysia Duchenne Muscular Dystrophy (DMD) Therapeutics Consumption and Growth Rate (2017-2022)

    • Figure Philippines Duchenne Muscular Dystrophy (DMD) Therapeutics Consumption and Growth Rate (2017-2022)

    • Figure Vietnam Duchenne Muscular Dystrophy (DMD) Therapeutics Consumption and Growth Rate (2017-2022)

    • Table South America Duchenne Muscular Dystrophy (DMD) Therapeutics Consumption by Country (2017-2022)

    • Figure Brazil Duchenne Muscular Dystrophy (DMD) Therapeutics Consumption and Growth Rate (2017-2022)

    • Figure Colombia Duchenne Muscular Dystrophy (DMD) Therapeutics Consumption and Growth Rate (2017-2022)

    • Figure Chile Duchenne Muscular Dystrophy (DMD) Therapeutics Consumption and Growth Rate (2017-2022)

    • Figure Argentina Duchenne Muscular Dystrophy (DMD) Therapeutics Consumption and Growth Rate (2017-2022)

    • Figure Venezuela Duchenne Muscular Dystrophy (DMD) Therapeutics Consumption and Growth Rate (2017-2022)

    • Figure Peru Duchenne Muscular Dystrophy (DMD) Therapeutics Consumption and Growth Rate (2017-2022)

    • Figure Puerto Rico Duchenne Muscular Dystrophy (DMD) Therapeutics Consumption and Growth Rate (2017-2022)

    • Figure Ecuador Duchenne Muscular Dystrophy (DMD) Therapeutics Consumption and Growth Rate (2017-2022)

    • Table GCC Duchenne Muscular Dystrophy (DMD) Therapeutics Consumption by Country (2017-2022)

    • Figure Bahrain Duchenne Muscular Dystrophy (DMD) Therapeutics Consumption and Growth Rate (2017-2022)

    • Figure Kuwait Duchenne Muscular Dystrophy (DMD) Therapeutics Consumption and Growth Rate (2017-2022)

    • Figure Oman Duchenne Muscular Dystrophy (DMD) Therapeutics Consumption and Growth Rate (2017-2022)

    • Figure Qatar Duchenne Muscular Dystrophy (DMD) Therapeutics Consumption and Growth Rate (2017-2022)

    • Figure Saudi Arabia Duchenne Muscular Dystrophy (DMD) Therapeutics Consumption and Growth Rate (2017-2022)

    • Figure United Arab Emirates Duchenne Muscular Dystrophy (DMD) Therapeutics Consumption and Growth Rate (2017-2022)

    • Table Africa Duchenne Muscular Dystrophy (DMD) Therapeutics Consumption by Country (2017-2022)

    • Figure Nigeria Duchenne Muscular Dystrophy (DMD) Therapeutics Consumption and Growth Rate (2017-2022)

    • Figure South Africa Duchenne Muscular Dystrophy (DMD) Therapeutics Consumption and Growth Rate (2017-2022)

    • Figure Egypt Duchenne Muscular Dystrophy (DMD) Therapeutics Consumption and Growth Rate (2017-2022)

    • Figure Algeria Duchenne Muscular Dystrophy (DMD) Therapeutics Consumption and Growth Rate (2017-2022)

    • Table Oceania Duchenne Muscular Dystrophy (DMD) Therapeutics Consumption by Country (2017-2022)

    • Figure Australia Duchenne Muscular Dystrophy (DMD) Therapeutics Consumption and Growth Rate (2017-2022)

    • Figure New Zealand Duchenne Muscular Dystrophy (DMD) Therapeutics Consumption and Growth Rate (2017-2022)

    • Table Sarepta Therapeutics Inc Company Details

    • Table Sarepta Therapeutics Inc Duchenne Muscular Dystrophy (DMD) Therapeutics Sales, Price, Value and Gross Profit (2017-2022)

    • Table Sarepta Therapeutics Inc Duchenne Muscular Dystrophy (DMD) Therapeutics Main Business and Markets Served

    • Table Sarepta Therapeutics Inc Duchenne Muscular Dystrophy (DMD) Therapeutics Product Portfolio

    • Table F Hoffmann-La Roche Ltd Company Details

    • Table F Hoffmann-La Roche Ltd Duchenne Muscular Dystrophy (DMD) Therapeutics Sales, Price, Value and Gross Profit (2017-2022)

    • Table F Hoffmann-La Roche Ltd Duchenne Muscular Dystrophy (DMD) Therapeutics Main Business and Markets Served

    • Table F Hoffmann-La Roche Ltd Duchenne Muscular Dystrophy (DMD) Therapeutics Product Portfolio

    • Table Italfarmaco Company Details

    • Table Italfarmaco Duchenne Muscular Dystrophy (DMD) Therapeutics Sales, Price, Value and Gross Profit (2017-2022)

    • Table Italfarmaco Duchenne Muscular Dystrophy (DMD) Therapeutics Main Business and Markets Served

    • Table Italfarmaco Duchenne Muscular Dystrophy (DMD) Therapeutics Product Portfolio

    • Table Wave Life Sciences Ltd Company Details

    • Table Wave Life Sciences Ltd Duchenne Muscular Dystrophy (DMD) Therapeutics Sales, Price, Value and Gross Profit (2017-2022)

    • Table Wave Life Sciences Ltd Duchenne Muscular Dystrophy (DMD) Therapeutics Main Business and Markets Served

    • Table Wave Life Sciences Ltd Duchenne Muscular Dystrophy (DMD) Therapeutics Product Portfolio

    • Table PTC Therapeutics Inc Company Details

    • Table PTC Therapeutics Inc Duchenne Muscular Dystrophy (DMD) Therapeutics Sales, Price, Value and Gross Profit (2017-2022)

    • Table PTC Therapeutics Inc Duchenne Muscular Dystrophy (DMD) Therapeutics Main Business and Markets Served

    • Table PTC Therapeutics Inc Duchenne Muscular Dystrophy (DMD) Therapeutics Product Portfolio

    • Figure Global Pain Management Drugs Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Corticosteroids Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Prednisone Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Deflazacort Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Others Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Hospitals Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Clinics Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Home Care Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Duchenne Muscular Dystrophy (DMD) Therapeutics Consumption Forecast by Country (2022-2028)

    • Table North America Duchenne Muscular Dystrophy (DMD) Therapeutics Consumption Forecast by Country (2022-2028)

    • Figure United States Duchenne Muscular Dystrophy (DMD) Therapeutics Consumption Forecast and Growth Rate (2022-2028)

    • Figure Canada Duchenne Muscular Dystrophy (DMD) Therapeutics Consumption Forecast and Growth Rate (2022-2028)

    • Figure Mexico Duchenne Muscular Dystrophy (DMD) Therapeutics Consumption Forecast and Growth Rate (2022-2028)

    • Table Europe Duchenne Muscular Dystrophy (DMD) Therapeutics Consumption Forecast by Country (2022-2028)

    • Figure Germany Duchenne Muscular Dystrophy (DMD) Therapeutics Consumption Forecast and Growth Rate (2022-2028)

    • Figure UK Duchenne Muscular Dystrophy (DMD) Therapeutics Consumption Forecast and Growth Rate (2022-2028)

    • Figure Spain Duchenne Muscular Dystrophy (DMD) Therapeutics Consumption Forecast and Growth Rate (2022-2028)

    • Figure Belgium Duchenne Muscular Dystrophy (DMD) Therapeutics Consumption Forecast and Growth Rate (2022-2028)

    • Figure France Duchenne Muscular Dystrophy (DMD) Therapeutics Consumption Forecast and Growth Rate (2022-2028)

    • Figure Italy Duchenne Muscular Dystrophy (DMD) Therapeutics Consumption Forecast and Growth Rate (2022-2028)

    • Figure Denmark Duchenne Muscular Dystrophy (DMD) Therapeutics Consumption Forecast and Growth Rate (2022-2028)

    • Figure Finland Duchenne Muscular Dystrophy (DMD) Therapeutics Consumption Forecast and Growth Rate (2022-2028)

    • Figure Norway Duchenne Muscular Dystrophy (DMD) Therapeutics Consumption Forecast and Growth Rate (2022-2028)

    • Figure Sweden Duchenne Muscular Dystrophy (DMD) Therapeutics Consumption Forecast and Growth Rate (2022-2028)

    • Figure Poland Duchenne Muscular Dystrophy (DMD) Therapeutics Consumption Forecast and Growth Rate (2022-2028)

    • Figure Russia Duchenne Muscular Dystrophy (DMD) Therapeutics Consumption Forecast and Growth Rate (2022-2028)

    • Figure Turkey Duchenne Muscular Dystrophy (DMD) Therapeutics Consumption Forecast and Growth Rate (2022-2028)

    • Table APAC Duchenne Muscular Dystrophy (DMD) Therapeutics Consumption Forecast by Country (2022-2028)

    • Figure China Duchenne Muscular Dystrophy (DMD) Therapeutics Consumption Forecast and Growth Rate (2022-2028)

    • Figure Japan Duchenne Muscular Dystrophy (DMD) Therapeutics Consumption Forecast and Growth Rate (2022-2028)

    • Figure India Duchenne Muscular Dystrophy (DMD) Therapeutics Consumption Forecast and Growth Rate (2022-2028)

    • Figure South Korea Duchenne Muscular Dystrophy (DMD) Therapeutics Consumption Forecast and Growth Rate (2022-2028)

    • Figure Pakistan Duchenne Muscular Dystrophy (DMD) Therapeutics Consumption Forecast and Growth Rate (2022-2028)

    • Figure Bangladesh Duchenne Muscular Dystrophy (DMD) Therapeutics Consumption Forecast and Growth Rate (2022-2028)

    • Figure Indonesia Duchenne Muscular Dystrophy (DMD) Therapeutics Consumption Forecast and Growth Rate (2022-2028)

    • Figure Thailand Duchenne Muscular Dystrophy (DMD) Therapeutics Consumption Forecast and Growth Rate (2022-2028)

    • Figure Singapore Duchenne Muscular Dystrophy (DMD) Therapeutics Consumption Forecast and Growth Rate (2022-2028)

    • Figure Malaysia Duchenne Muscular Dystrophy (DMD) Therapeutics Consumption Forecast and Growth Rate (2022-2028)

    • Figure Philippines Duchenne Muscular Dystrophy (DMD) Therapeutics Consumption Forecast and Growth Rate (2022-2028)

    • Figure Vietnam Duchenne Muscular Dystrophy (DMD) Therapeutics Consumption Forecast and Growth Rate (2022-2028)

    • Table South America Duchenne Muscular Dystrophy (DMD) Therapeutics Consumption Forecast by Country (2022-2028)

    • Figure Brazil Duchenne Muscular Dystrophy (DMD) Therapeutics Consumption Forecast and Growth Rate (2022-2028)

    • Figure Colombia Duchenne Muscular Dystrophy (DMD) Therapeutics Consumption Forecast and Growth Rate (2022-2028)

    • Figure Chile Duchenne Muscular Dystrophy (DMD) Therapeutics Consumption Forecast and Growth Rate (2022-2028)

    • Figure Argentina Duchenne Muscular Dystrophy (DMD) Therapeutics Consumption Forecast and Growth Rate (2022-2028)

    • Figure Venezuela Duchenne Muscular Dystrophy (DMD) Therapeutics Consumption Forecast and Growth Rate (2022-2028)

    • Figure Peru Duchenne Muscular Dystrophy (DMD) Therapeutics Consumption Forecast and Growth Rate (2022-2028)

    • Figure Puerto Rico Duchenne Muscular Dystrophy (DMD) Therapeutics Consumption Forecast and Growth Rate (2022-2028)

    • Figure Ecuador Duchenne Muscular Dystrophy (DMD) Therapeutics Consumption Forecast and Growth Rate (2022-2028)

    • Table GCC Duchenne Muscular Dystrophy (DMD) Therapeutics Consumption Forecast by Country (2022-2028)

    • Figure Bahrain Duchenne Muscular Dystrophy (DMD) Therapeutics Consumption Forecast and Growth Rate (2022-2028)

    • Figure Kuwait Duchenne Muscular Dystrophy (DMD) Therapeutics Consumption Forecast and Growth Rate (2022-2028)

    • Figure Oman Duchenne Muscular Dystrophy (DMD) Therapeutics Consumption Forecast and Growth Rate (2022-2028)

    • Figure Qatar Duchenne Muscular Dystrophy (DMD) Therapeutics Consumption Forecast and Growth Rate (2022-2028)

    • Figure Saudi Arabia Duchenne Muscular Dystrophy (DMD) Therapeutics Consumption Forecast and Growth Rate (2022-2028)

    • Figure United Arab Emirates Duchenne Muscular Dystrophy (DMD) Therapeutics Consumption Forecast and Growth Rate (2022-2028)

    • Table Africa Duchenne Muscular Dystrophy (DMD) Therapeutics Consumption Forecast by Country (2022-2028)

    • Figure Nigeria Duchenne Muscular Dystrophy (DMD) Therapeutics Consumption Forecast and Growth Rate (2022-2028)

    • Figure South Africa Duchenne Muscular Dystrophy (DMD) Therapeutics Consumption Forecast and Growth Rate (2022-2028)

    • Figure Egypt Duchenne Muscular Dystrophy (DMD) Therapeutics Consumption Forecast and Growth Rate (2022-2028)

    • Figure Algeria Duchenne Muscular Dystrophy (DMD) Therapeutics Consumption Forecast and Growth Rate (2022-2028)

    • Table Oceania Duchenne Muscular Dystrophy (DMD) Therapeutics Consumption Forecast by Country (2022-2028)

    • Figure Australia Duchenne Muscular Dystrophy (DMD) Therapeutics Consumption Forecast and Growth Rate (2022-2028)

    • Figure New Zealand Duchenne Muscular Dystrophy (DMD) Therapeutics Consumption Forecast and Growth Rate (2022-2028)

Report Version Choose

Report

BUY NOW

Our Customers

Beyond grateful for the confidence and support from all partners and customers.A win-win situation is our ultimate pursuit.

Beyond Consulting, Future is Feasible

We provide more professional and intelligent market reports to complement your business decisions.

CONTACT US